Sunday, August 01, 2021

by Physicians Office Resource 

Meet Bindex® – the revolutionary, portable bone density scanning device that could be the new gold standard in first-level osteoporosis diagnostics.

For over 30 years, DXA bone density scanning has been the most reliable and the most accurate way to diagnose and monitor osteoporosis. But could it be missing the mark?

Osteoporotic fractures account for more hospitalizations than breast cancer, diabetes and myocardial infarction combined.¹ Yet while the entire Medicare population of around 60 million

is at risk of osteoporosis, only 2.5 million DXA scans are performed annually.

While its accuracy is not in question, does the very nature of DXA – high cost, limited to those with appropriate insurance coverage, less than universal availability – ignore all but the most at-risk patients, those who might already have been identified as osteoporosis sufferers? Could there, in fact, be an easier, more inclusive yet comparably accurate way to assess bone density?

The osteoporosis diagnosis gap

The discrepancy between patients at risk for osteoporosis and the number of DXA scans performed annually may be attributed to several factors.

Patients without an osteoporosis diagnosis who are at risk because of their age, gender or other health issues may not all be eligible for a DXA scan. Younger at-risk patients may not be eligible because of their age.

Many health insurance plans cover only eligible patients (which often means patients over 65) and only for one DXA scan every two years (when osteoporosis is diagnosed) even though more frequent scanning may allow physicians to offer more timely, more customized and, potentially, more effective treatment.

Bone density scanning made easier

There is, clearly, a need for accurate bone density scanning that is both easier and more affordable for patients, especially Medicare-eligible patients. The answer may come in the form

of an outwardly simple but technologically advanced handheld device called Bindex.

Designed and manufactured by Bone Index Ltd, Bindex promises a more equitable arrangement that potentially allows more at-risk patients – of Medicare age and younger, with or without an existing diagnosis – to receive fast and accurate bone density scans in a doctor’s office, clinic or any setting.

Bindex is 90% accurate in detecting osteoporosis

Extensive clinical research has proven Bindex to be 90% accurate in detecting osteoporosis which means it can replace nearly 70% of DXA scans for patients with suspected osteoporosis.

Using safe pulse-echo ultrasound, handheld Bindex measures cortical bone thickness in seconds and instantly analyzes bone density, generating a detailed yet easy-to-read report.

Better for patients – with clear advantages for doctors

Its size and portability means that Bindex can be used anywhere – in physician’s offices, hospitals and clinics as well as in patients’ homes and at bone density screening events. A

Bindex scan costs a fraction of a DXA scan and, for many patients, particularly those who want more frequent screenings than allowed by their insurance, represents a very affordable

out-of-pocket medical expense.

Bindex means that physicians can diagnose more at-risk patients and scan more diagnosed patients more frequently, and so make timely treatment decisions and adjustments. It

may also be a useful patient acquisition and retention tool, especially as patients age into Medicare, allowing physicians to keep an important source of patient revenue within their

own practices.

An opportunity to trial Bindex at no cost

Bone Index Ltd, manufacturer of Bindex, is currently offering selected US-based physicians the opportunity to be part of the device’s US launch by trialing Bindex with patients at no cost.

To register your interest in participating in the trial, please visit Bindex.us/launch or call

(970)-306-7452.

Footnote:

1. International Osteoporosis Foundation

Designed and developed by Bone Index Ltd, a healthcare diagnostics company, Bindex is

FDA-cleared and has been validated in clinical trials with several thousand patients. This

revolutionary device has already screened over 1.6 million people in the US, and has 19

global patents in the US, China, Japan and major EU countries.